COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

Protocol No
REGENERON-R5459-ONC-1888
Principal Investigator
Parameswaran Hari
Phase
I/II
Summary
REGN5459 is an antibody. An antibody is a kind of protein that your immune (defense) system normally makes to fight bacteria and viruses. REGN5459 is a type of antibody called a bispecific antibody, because it is designed to bind to 2 different cell proteins. REGN5459 binds to BCMA (B-cell maturation antigen) and CD3 (cluster of differentiation 3), which are each found on the surface of different types of cells in the body. Proteins are part of each cell in your body, and proteins work together for the cell to function. BCMA is found on the surface of multiple myeloma cells. CD3 is a protein that is found on the surface of T-cells (also called lymphocytes), which are a type of white blood cell in the body that is part of the immune system that fights infections and cancer. In test environments, REGN5459 triggers activation of lymphocytes only in the presence of cells that have BCMA on their surface.
Description
The main purpose of this study is to learn about the safety of REGN5459 and to find out what is the best dose of REGN5459 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5459 can treat your cancer.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL